Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 102Breast Neoplasms 10Neoplasm Metastasis 8Prostatic Neoplasms, Castration-Resistant 6Triple Negative Breast Neoplasms 5Castration-resistant Prostate Cancer 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Metastatic Castration-resistant Prostate Cancer 3Prostate Cancer Metastatic 2Prostate Adenocarcinoma 2Ovarian Neoplasms 2Neoplasms 2Metastatic Castration-Resistant Prostate Cancer (mCRPC) 2Metastatic Castration-Resistant Prostate Cancer 2Metastatic Castration Resistant Prostate Cancer 2Castration Resistant Metastatic Prostate Cancer 2Carcinoma, Hepatocellular 2Adenocarcinoma of the Prostate 2Adenocarcinoma 2Uterine Cervical Neoplasms 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Ureteral Diseases 1Thrombocytosis 1Stomach Neoplasms 1Solid Tumor 1Salivary Cancer 1Recurrent Endometrial Endometrioid Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 5luprolide acetate gel depot 3Radiotherapy 3Radiosurgery 3Radiation 3Leuprolide 3Goserelin 3relugolix 2gallium 68 PSMA-11 2enzalutamide 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Triptorelin Pamoate 2radium Ra 223 dichloride 1niraparib 1histrelin 1fluciclovine F-18 1flibanserin 1entinostat 1darolutamide 1bicalutamide 1atezolizumab 1apalutamide 1abiraterone 1X-Rays 1Watchful Waiting 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Specimen Handling 1Salicylic Acid 1Receptors, Bombesin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Prostate Adenocarcinoma × enzalutamide × Clear all
NCT06499870 2026-06-05

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

Northwestern University

Phase 2 Recruiting
50 enrolled
Genitourinary

Prostate Adenocarcinoma

NCT03829930 2021-08-02

Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer

George Washington University

Phase 1 Terminated
6 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡